Original Article

Antimicrobial resistance pattern of Gram-positive bacteria during three consecutive years at the nephrology ward of a tertiary referral hospital in Shiraz, Southwest Iran

Iman Karimzadeh¹, Mona Mirzaee¹, Niloofar Sadeghimanesh¹, Mohammad Mahdi Sagheb²

ABSTRACT

Objective: The aim of the present study was to determine the pattern of antimicrobial resistance of Gram-positive bacteria during three consecutive years at the nephrology ward of Namazi Hospital in Shiraz, Southwest of Iran.

Methods: During a 3-year period from 2013 to 2015, data of all biological samples of hospitalized patients at the adult nephrology ward of Namazi Hospital were sent to the central laboratory for identification of Gram-positive microorganisms and subsequently, their antimicrobial susceptibility testing by Kirby–Bauer disc diffusion method were analyzed in a retrospective manner.

Findings: Coagulase-negative Staphylococci (CONS) (38.5%), Staphylococcus aureus (25.4%), and Enterococcus spp. (23.8%) were the most common isolated Gram-positive bacteria from all biological samples. All Enterococcus spp. isolates within the 3 years were resistant to oxacillin. The rate of vancomycin-resistant enterococci (VRE) increased from 40.63% in 2013 to 72.73% in 2015. Enterococcus spp. resistance rates to aminoglycosides during 3 years were above 85%. The frequencies of oxacillin-resistant S. aureus (ORSA) in 2013, 2014, and 2015 were 95.24%, 80.95%, and 36.36%, respectively. Two out of 11 (6.67%) S. aureus isolates were resistant to vancomycin. More than 90% of CONS were sensitive to vancomycin within the study period. The frequency of gentamicin-resistant CONS ranged from 40% to 57.14%.

Conclusion: The rates of ORSA, VRE, and aminoglycoside-resistant CONS as well as Enterococcus spp. in our clinical setting were considerably high and concerning. These may be due to the failure or lack of infection control activities and antimicrobial selection pressure.

Keywords: Antibiotic; Gram-positive microorganisms; nephrology; resistance pattern

INTRODUCTION

Infectious diseases are among the most important causes of morbidity and mortality worldwide.¹ Spread of resistant microorganisms is playing a significant role in this regard.² In the United States, it has been estimated that 50–60% of all nosocomial infections are caused by antibiotic-resistant bacteria.³ Although global data are insufficient, the burden of antibacterial resistance in the United States has been reported to

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Karimzadeh I, Mirzaee M, Sadeghimanesh N, Sagheb MM. Antimicrobial resistance pattern of Gram-positive bacteria during three consecutive years at the nephrology ward of a tertiary referral hospital in Shiraz, Southwest Iran. J Res Pharm Pract 2016;5:238-47.
be 23,000 deaths per year. Beside mortality, the direct and indirect overall societal costs of antibacterial resistance in the US have been estimated to be $20 and $35 billion, respectively. In the European Union countries, an estimated 25,000 deaths are attributed to antibiotic-resistant infections, costing €1.5 billion annually in both direct and indirect costs. In these countries, antibacterial resistance led to 16 million extra days of hospitalization.[4] In several hospital settings in the US and Europe, about 40% of antibacterial prescriptions are reported to be inappropriate.[5] Findings from a study in six teaching hospitals at Shiraz from February to July 2004 demonstrated that antibiotics are inappropriately used in 98% of patients undergoing surgery.[6]

Among pathogens, Gram-positive bacteria, especially *Staphylococcus aureus* and *Streptococcus pneumoniae* are responsible for a large number of both community-acquired and health-care associated infections at different sites including bone and joint, upper and lower respiratory tract, bloodstream, central nervous system, and skin and soft tissue.[7] Among Gram-positive bacteria, methicillin-resistant *S. aureus* (MRSA), vancomycin-resistant enterococci (VRE), and coagulase negative staphylococci (CONS) become major problems in clinical settings due to high morbidity as well as mortality and limited treatment options.[8-10] In contrast to Gram-negative infections, the prevalence and resistance pattern of Gram-positive pathogens have not been studied well worldwide. This issue has been largely overlooked in developing countries such as Iran. Knowledge about the most common causative microorganisms and their resistance pattern can be exploited to help clinicians in selecting an optimized antimicrobial agent for empirical therapy and developing rational prescription guidelines for definite therapy. The main purpose of the current study was to determine the pattern of antimicrobial sensitivity of Gram-positive bacteria during three consecutive years at the nephrology ward of a tertiary referral hospital in Shiraz.

**METHODS**

This retrospective study was performed on microbiological records of patients hospitalized at a 20-bed adult nephrology ward of Namazi Hospital, a multispecialty healthcare university setting affiliated to Shiraz University of Medical Sciences, between 2013 and 2015. The study was approved by the Institutional Review Board and the Medical Ethics Committee of the hospital.

Biological isolates of hospitalized patients such as blood, urine, sputum, wound drainage, abscess, synovial, pleural, ascitic, and cerebrospinal fluid were sent to the central laboratory of the hospital. They were taken either before (as empirical therapy) or during antibacterial treatment (as definite therapy) for assessing microbiological response of both community-acquired and nosocomial infections. Identification of bacteria was performed by the initial Gram-staining and additional biochemical tests such as catalase, coagulase, and DNase. Mueller-Hinton agar culture medium (Merck, Germany) was inoculated with a saline suspension of isolated aerobic Gram-positive bacteria equivalent to McFarland 0.5 standard. After that, antibiotic discs (Padtan Teb Co., Iran) were placed on the surface of the agar. The antimicrobial susceptibilities of Gram-positive bacteria were determined by the Kirby-Bauer disc diffusion method based on the Clinical and Laboratory Standard Institute guidelines.[11] After 16–18 h incubation at 37°C, the isolated aerobic Gram-positive bacteria were categorized to be resistant, intermediate resistant, or sensitive based on the size of inhibition zone. The antibiotic discs (per unit disc) used for antimicrobial susceptibility of Gram-positive bacteria were as follows: oxacillin (5 mcg), ampicillin (10 mcg), cephalaxin (30 mcg), ceftriaxone (30 mcg), cefotaxime (30 mcg), ceftizoxime (30 mcg), erythromycin (5 mcg), azithromycin (15 mcg), clindamycin (2 mcg), trimethoprim/sulfamethoxazole (25 [1.25/23.75] mcg), gentamicin (10 mcg), amikacin (30 mcg), vancomycin (30 mcg), ciprofloxacin (5 mcg), ofloxacin (5 mcg), nitrofurantoin (300 mcg), and chloramphenicol (30 mcg).

Categorical variables were expressed as percentage. Descriptive analyses were carried out by the Statistical Package for the Social Sciences (SPSS) version 20 software (IBM company, New York, NY, United States).

**RESULTS**

During the 3-year period, 374 Gram-positive bacteria were isolated from biological samples. The three most common isolated Gram-positive bacteria from all samples were *S. aureus* (38.30%), CONS (25.26%), and Enterococcus spp. (23.67%). Most Gram-positive bacteria were isolated from urine (37.97%) followed by blood (36.10%) [Table 1].

The 3-year antimicrobial resistance pattern of Gram-positive bacteria to different antimicrobials is demonstrated in Tables 2 and 3. The highest (68.6–78.1%) and lowest (14.85–39.29%) antibacterial resistance rates were seen with Enterococcus spp. and *S. aureus*, respectively. Regarding the antibacterial agent, the most frequent resistance was associated, with ofloxacin (80–90.91%) and oxacillin (79.31–86.67%). Nitrofurantoin, vancomycin,
and chloramphenicol were identified as the most active antibacterial agents with the resistance rates of 3.7–10%, 9.52–23.88%, and 17.44–26.92%, respectively.

Regarding Enterococcus spp., all (100%) isolates within the 3 years were resistant to oxacillin. The sensitivity rate of Enterococcus spp. to vancomycin decreased from 34.37% in 2013 to 13.64% in 2015. In other words, the rate of VRE increased from 40.63% in 2013 to 72.73% in 2015. Enterococcus spp. resistance rate to aminoglycosides in 2013, 2014, and 2015 were 92.86%, 88%, and 91.3%, respectively. Resistance rate of Enterococcus spp. to ampicillin was 100% in 2013, 46.4% in 2014, and 66.67% in 2015.

The frequency of oxacillin-resistant *S. aureus* (ORSA) from isolated samples in 2013, 2014, and 2015 was 95.24%, 80.95%, and 36.36%, respectively. During the study period, two out of 11 (6.67%) *S. aureus* isolates were resistant to vancomycin. The sensitivity rate of *S. aureus* to clindamycin was 63.64% in 2014 and 66.67% in 2015. *S. aureus* sensitivity rates to trimethoprim/sulfamethoxazole in 2013, 2014, and 2015 were 95.45%, 66.67%, and 90.91%, respectively.

The sensitivity rate of CONS to vancomycin was 97.87% in 2013, 98.08% in 2014, and 93.55% in 2015. CONS resistance rates to oxacillin in 2013 and 2015 were reported to be 90.32% and 73.91%, respectively. The frequency of gentamicin-resistant CONS was 54.05% in 2013, 40% in 2014, and 57.14% in 2015.

Regarding *Streptococcus* spp., the rate of resistance to ceftriaxone in 2013, 2014, and 2015 was 75%, 23.08%, and 14.29%, respectively. The frequency of vancomycin-resistant *Streptococcus* spp. in 2013 was 23.08% and in 2014 was 21.43%. All (100%) *Streptococcus* spp. isolates were sensitive to vancomycin in 2015. In contrast, all *Streptococcus* spp. isolates were resistant to azithromycin in 2013 and 2014. About 80%, 50%, and 17% of *Streptococcus* spp. samples were resistant to ciprofloxacin in 2013, 2014, and 2015, respectively.

**DISCUSSION**

In the present study, *S. aureus* was the most frequent Gram-positive pathogen isolated from all samples. This is consistent with Japoni *et al.* survey between January 2001 and December 2004 on 9407 referred blood samples from patients at three main wards, neonates, pediatrics, and adults of Namazi Hospital.[13] The same study group identified *S. aureus* as the second most prevalent pathogenic bacteria isolated from 58 patients with nosocomial pneumonia over 9 months in the aforementioned clinical setting.[13] Among 97 samples of 46 patients with Intensive Care Unit (ICU)-acquired infections, *S. aureus* was the most prevalent Gram-positive pathogen from eight ICUs of two major teaching hospitals in Shiraz.[14] Similar findings have been reported from some other hospitals in Iran such as Khalili *et al.*[15] and Soltani *et al.*[16] from Imam Khomeini Hospital at Tehran.

Although it varied in different years, the frequency of ORSA in the current study was considerably high. However, the rate of ORSA was descending during the study period (from 95.24% to 36.36%). The definite explanation for the latter finding in our center was unknown. Lack of adequate antibiotic discs for assessing antibacterial resistance and invalid techniques of isolating and culturing bacteria in years 2013 and 2014 may be account for these results. In this regards, the sum number of *S. aureus* in the years 2013 and 2014 was 12 isolates, much less than that in 2015 (41 isolates). In contrast, the resistance rate of *S. aureus* to oxacillin increased from 60.78% to 72% during 4 years at a referral infectious diseases ward in Tehran.[13] The rate of MRSA in a nephrology ward at Tehran was 58.3%.[17] Hassanzadeh *et al.* reported all 9 (100%) *S. aureus* isolates from Namazi and Faghihi ICUs in Shiraz were resistant to cefoxitin (as a suggested index of MRSA).[14] The rate of MRSA reported from other studies in Iran ranges from 40% to 100%.[15,18] This ranges between 30% and 40% in different regions of the neighboring country, Saudi Arabia.[19] MRSA frequency largely depends on several factors such as infection control activities and antimicrobial selection pressure. Regarding the first issue; for example, it has been demonstrated that rigorous infection control practices set by the government in the United Kingdom have resulted in the sharp fall in MRSA prevalence from 40–45% during 2001–2005 to 36% in 2007.[20] In relation to antimicrobial selection pressure, beta lactams including amoxicillin, cefixime, and penicillin 6.3.3 are among the 10 most commonly prescribed medications by physicians in Iran based on the last National Rational Drug Use Committee official report in 2010.[21] According to our data, trimethoprim/
Table 2: Sensitivity, intermediate resistance, and resistance frequencies of isolated Gram-positive bacteria to different antimicrobials during three sequential years

| Antimicrobial agent/microorganism | Sensitive (n) | Intermediate (n) | Resistant (n) |
|----------------------------------|--------------|-----------------|--------------|
|                                  | 2013 | 2014 | 2015 | 2013 | 2014 | 2015 | 2013 | 2014 | 2015 |
| Trimethoprim/sulfamethoxazole     |      |      |      |      |      |      |      |      |      |
| *Streptococcus* spp.              | 2    | 6    | -    | 1    | 2    | 2    | 9    | 11   | 1    |
| *S. aureus*                      | 21   | 18   | 9    | -    | -    | -    | 1    | 7    | 1    |
| Coagulase negative staphylococci | 3    | 21   | 11   | -    | 1    | -    | 5    | 26   | 18   |
| Enterococcus spp.                | -    | 5    | 3    | -    | -    | 3    | 22   | 25   | 18   |
| Total                            | 26   | 50   | 23   | 1    | 3    | 5    | 37   | 69   | 38   |
| Percentage                       | 40.63| 40.98| 34.85| 1.56 | 2.46 | 7.58 | 57.81| 56.56| 57.58|
| Amikacin                         |      |      |      |      |      |      |      |      |      |
| *Streptococcus* spp.             | -    | 2    | 1    | -    | -    | -    | 10   | 13   | 5    |
| *S. aureus*                      | 1    | -    | -    | -    | -    | -    | 1    | 3    | 1    |
| Coagulase negative staphylococci | 7    | 10   | 1    | -    | 1    | 1    | 5    | 1    | 1    |
| Enterococcus spp.                | 1    | -    | -    | -    | -    | -    | 8    | 20   | 9    |
| Total                            | 9    | 12   | 2    | -    | 1    | 1    | 24   | 37   | 16   |
| Percentage                       | 27.27| 24   | 10.53| -    | 2    | 5.26 | 72.73| 74   | 84.21|
| Gentamicin                       |      |      |      |      |      |      |      |      |      |
| *Streptococcus* spp.             | 1    | 4    | 1    | -    | 1    | -    | 10   | 13   | 4    |
| *S. aureus*                      | 18   | 12   | 10   | 3    | 2    | -    | 14   | 11   | -    |
| Coagulase negative staphylococci | 17   | 28   | 8    | -    | 2    | 3    | 20   | 20   | 16   |
| Enterococcus spp.                | 2    | 1    | 1    | -    | 4    | 1    | 18   | 24   | 12   |
| Total                            | 38   | 45   | 20   | 3    | 9    | 4    | 62   | 69   | 32   |
| Percentage                       | 36.89| 36.59| 35.71| 2.91 | 7.32 | 7.14 | 60.19| 56.1 | 57.14|
| Ciprofloxacin                    |      |      |      |      |      |      |      |      |      |
| *Streptococcus* spp.             | 1    | 5    | 3    | -    | 5    | 2    | 12   | 8    | 1    |
| *S. aureus*                      | 18   | 12   | 10   | 3    | 2    | 1    | 3    | 14   | 1    |
| Coagulase negative staphylococci | 10   | 21   | 11   | -    | 1    | -    | 3    | 26   | 18   |
| Enterococcus spp.                | 1    | -    | 1    | 2    | -    | 1    | 17   | 30   | 18   |
| Total                            | 12   | 36   | 25   | 5    | 8    | 4    | 35   | 78   | 38   |
| Percentage                       | 23.08| 29.51| 37.31| 9.62 | 6.56 | 5.97 | 67.31| 63.93| 56.72|
| Ofloxacin                        |      |      |      |      |      |      |      |      |      |
| *Streptococcus* spp.             | -    | 1    | -    | -    | -    | -    | 4    | 3    | -    |
| Coagulase negative staphylococci | -    | -    | -    | -    | -    | -    | 1    | -    | -    |
| Enterococcus                     | 1    | -    | -    | -    | -    | -    | 5    | 5    | 5    |
| Total                            | 1    | 1    | 1    | -    | 1    | -    | 10   | 8    | 5    |
| Percentage                       | 9.09 | 10   | 16.67| -    | 10   | -    | 90.91| 80   | 83.33|
| Nitrofurantoin                   |      |      |      |      |      |      |      |      |      |
| *Streptococcus* spp.             | -    | 10   | 6    | 1    | 2    | -    | 1    | 2    | -    |
| *S. aureus*                      | 2    | 3    | 1    | -    | -    | -    | -    | -    | -    |
| Coagulase negative staphylococci | 13   | 11   | 2    | -    | 1    | 2    | -    | -    | -    |
| Enterococcus spp.                | -    | 20   | 8    | 2    | 5    | 4    | 1    | -    | 2    |
| Total                            | 15   | 44   | 17   | 3    | 8    | 6    | 2    | 2    | 2    |
| Percentage                       | 75   | 81.48| 68   | 15   | 14.81| 24   | 10   | 3.7  | 8    |
| Ceftriaxone                      |      |      |      |      |      |      |      |      |      |
| *Streptococcus* spp.             | 2    | 10   | 5    | -    | -    | -    | 6    | 4    | 1    |
| *S. aureus*                      | 1    | -    | 1    | -    | -    | -    | 3    | -    | -    |
| Coagulase negative staphylococci | 4    | 6    | -    | -    | -    | 1    | 7    | 6    | 3    |
| Total                            | 7    | 16   | 6    | 1    | 1    | 1    | 13   | 13   | 4    |
| Percentage                       | 33.33| 53.33| 54.55| 4.76 | 3.33 | 9.09 | 61.9 | 43.33| 36.36|
| Cefotaxime                       |      |      |      |      |      |      |      |      |      |
| *Streptococcus* spp.             | -    | 2    | 3    | -    | -    | -    | -    | 3    | 1    |
| *S. aureus*                      | -    | -    | 1    | -    | -    | -    | -    | 2    | 1    |
| Coagulase negative staphylococci | -    | 1    | -    | -    | -    | -    | -    | 3    | 1    |
| Total                            | -    | 3    | 4    | -    | -    | -    | 1    | 8    | 3    |
| Percentage                       | -    | 27.27| 50   | -    | 12.5 | -    | 72.73| 37.5 |      |

Contd...
Table 2: Contd...

| Antimicrobial agent/microorganism | Sensitive (n) | Intermediate (n) | Resistant (n) |
|----------------------------------|--------------|-----------------|--------------|
|                                  | 2013 | 2014 | 2015 | 2013 | 2014 | 2015 | 2013 | 2014 | 2015 |
| Cefitoxime                        |      |      |      |      |      |      |      |      |      |
| Streptococcus spp.               | 3    | 8    | 1    | -    | -    | -    | -    | -    | 1    |
| S. aureus                        | 2    | -    | -    | -    | -    | -    | -    | -    | -    |
| Coagulase negative staphylococci | 4    | 3    | 2    | -    | -    | -    | 10   | -    | 1    |
| Total                            | 9    | 11   | 3    | -    | 2    | -    | 10   | 14   | 2    |
| Percentage                       | 47.37| 4.07 | 60   | -    | 7.41 | -    | 52.63| 51.85| 40   |
| Cephalexin                       |      |      |      |      |      |      |      |      |      |
| Streptococcus spp.               | 3    | 12   | 4    | -    | -    | 1    | -    | -    | 1    |
| S. aureus                        | -    | 10   | 8    | 2    | 2    | 1    | -    | 11   | 1    |
| Coagulase negative staphylococci | -    | 33   | 18   | 4    | -    | 1    | -    | 16   | 10   |
| Enterococcus spp.                | 1    | 4    | 1    | -    | 1    | 2    | 5    | 26   | 18   |
| Total                            | 4    | 59   | 31   | 6    | 3    | 5    | 5    | 60   | 30   |
| Percentage                       | 26.67| 48.36| 46.97| 40   | 15.56| -    | 52.63| 51.85| 40   |
| Ampicillin                       |      |      |      |      |      |      |      |      |      |
| Streptococcus spp.               | -    | 8    | 4    | -    | 1    | -    | 4    | 8    | 2    |
| Enterococcus spp.                | -    | 9    | 7    | -    | 6    | -    | 16   | 13   | 14   |
| Total                            | 1    | 17   | 11   | -    | 7    | -    | 20   | 21   | 16   |
| Percentage                       | 4.76 | 37.78| 40.74| 15.56| 95.24| 46.67| 45.45|      |      |
| Oxacillin                        |      |      |      |      |      |      |      |      |      |
| Streptococcus spp.               | -    | -    | -    | -    | -    | -    | 4    | 5    | -    |
| S. aureus                        | -    | 4    | 2    | 1    | -    | 2    | 20   | 12   | -    |
| Coagulase negative staphylococci | 3    | 6    | 1    | -    | -    | 1    | -    | 29   | 19   |
| Enterococcus spp.                | -    | -    | -    | -    | -    | -    | 2    | 8    | 4    |
| Total                            | 3    | 10   | 3    | 1    | -    | 3    | 26   | 54   | 23   |
| Percentage                       | 10   | 15.63| 10.34| 3.33 | -    | 10.34| 86.67| 46.38| 79.31|
| Vancomycin                       |      |      |      |      |      |      |      |      |      |
| Streptococcus spp.               | 8    | 13   | 5    | -    | 1    | -    | 3    | 3    | -    |
| S. aureus                        | -    | 28   | 11   | -    | -    | -    | -    | 2    | -    |
| Coagulase negative staphylococci | 46   | 51   | 29   | -    | 1    | -    | 1    | -    | -    |
| Enterococcus spp.                | 11   | 13   | 3    | 8    | 7    | 3    | 13   | 7    | 16   |
| Total                            | 65   | 105  | 48   | 8    | 9    | 3    | 17   | 12   | 16   |
| Percentage                       | 72.22| 83.33| 71.64| 8.89 | 7.14 | 4.48 | 18.89| 9.52 | 23.88|
| Erythromycin                     |      |      |      |      |      |      |      |      |      |
| Streptococcus spp.               | -    | -    | -    | -    | -    | -    | 4    | 4    | -    |
| S. aureus                        | -    | 10   | 7    | -    | -    | -    | -    | 11   | 3    |
| Coagulase negative staphylococci | 1    | 12   | 3    | -    | -    | -    | 23   | 19   | -    |
| Enterococcus spp.                | -    | -    | 1    | -    | -    | -    | 2    | 8    | 7    |
| Total                            | 1    | 22   | 11   | -    | -    | -    | 6    | 48   | 29   |
| Percentage                       | 14.29| 31.43| 27.5 | -    | -    | -    | 85.71| 68.57| 72.5 |
| Azithromycin                     |      |      |      |      |      |      |      |      |      |
| Streptococcus spp.               | -    | -    | -    | -    | -    | -    | 4    | 4    | -    |
| Total                            | -    | -    | -    | -    | -    | -    | 4    | 4    | 1    |
| Percentage                       | -    | -    | 50   | -    | -    | -    | 100  | 100  | 50   |
| Clindamycin                      |      |      |      |      |      |      |      |      |      |
| S. aureus                        | -    | 7    | 6    | -    | -    | -    | -    | 4    | 3    |
| Coagulase negative staphylococci | -    | 14   | 5    | -    | -    | 1    | -    | 9    | 17   |
| Enterococcus spp.                | -    | -    | 1    | -    | -    | -    | 3    | 5    | -    |
| Total                            | -    | 21   | 12   | -    | -    | 1    | -    | 16   | 25   |
| Percentage                       | -    | 56.76| 31.58| -    | 2.63 | -    | 43.24| 65.79| -    |
| Chloramphenicol                  |      |      |      |      |      |      |      |      |      |
| Streptococcus spp.               | 34   | 26   | 10   | -    | -    | 1    | 2    | 3    | -    |
| S. aureus                        | 2    | 37   | 20   | 1    | -    | -    | 10   | 6    | 5    |
| Coagulase negative staphylococci | 1    | 6    | 5    | -    | -    | -    | 2    | 3    | 3    |
| Enterococcus spp.                | 37   | 71   | 35   | 1    | -    | 1    | 14   | 15   | 8    |
| Total                            | 71.15| 82.56| 79.55| 1.92 | 2.27 | 26.92| 17.44| 18.18|      |

*S. aureus=Staphylococcus aureus*
Table 3: Sensitivity, intermediate resistance, and resistance frequencies of isolated Gram-positive bacteria to different antimicrobials during three sequential years

| Antimicrobial agent/microorganism                        | Sensitive (n) | Intermediate (n) | Resistant (n) |
|----------------------------------------------------------|---------------|-----------------|--------------|
|                                                          | 2013 | 2014 | 2015 | 2013 | 2014 | 2015 | 2013 | 2014 | 2015 |
| *Streptococcus* spp.                                      |      |      |      |      |      |      |      |      |      |
| Vancomycin                                                | 8    | 11   | 5    | 2    | -    | -    | 3    | 3    | -    |
| Gentamicin                                                | 1    | 2    | 1    | 2    | 11   | 1    | 10   | 12   | 4    |
| Amikacin                                                 | 1    | 1    | 1    | 1    | 1    | -    | 10   | 13   | 5    |
| Ciprofloxacin                                             | 1    | 3    | 3    | 2    | 5    | 2    | 12   | 8    | 1    |
| Ofloxacin                                                 | -    | -    | -    | 1    | -    | -    | 4    | 3    | -    |
| Trimethoprim/sulfamethoxazole                            | 1    | 4    | 2    | 2    | 2    | -    | 2    | 10   | 1    |
| Ampicillin                                                | -    | 6    | 4    | 2    | -    | -    | 4    | 8    | 2    |
| Oxacillin                                                 | -    | -    | -    | -    | 2    | -    | 4    | 3    | -    |
| Cephalexin                                                | 3    | 101  | 4    | 2    | -    | -    | -    | 6    | 1    |
| Ceftriaxone                                               | 2    | 10   | 5    | -    | 1    | -    | 6    | 3    | 1    |
| Cefotaxime                                                | 3    | 8    | 2    | -    | 1    | -    | -    | 2    | -    |
| Nitrofurantoin                                            | -    | 2    | -    | -    | -    | -    | -    | 3    | -    |
| Erythromycin                                              | -    | -    | -    | -    | -    | 2    | 4    | 4    | -    |
| Azithromycin                                              | -    | -    | -    | -    | 1    | -    | 5    | 3    | -    |
| Chloramphenicol                                           | -    | 1    | -    | 1    | -    | 1    | -    | 2    | -    |
| Total                                                     | 19   | 68   | 33   | 16   | 21   | 16   | 65   | 82   | 17   |
| Percentage                                                | 19   | 39.77 | 50   | 16   | 12.28 | 24.24 | 65   | 67.77 | 25.76 |
| *S. aureus*                                               |      |      |      |      |      |      |      |      |      |
| Vancomycin                                                | -    | 28   | 11   | -    | -    | -    | -    | 2    | -    |
| Gentamicin                                                | 18   | 12   | 10   | 3    | 2    | -    | 14   | 11   | 1    |
| Amikacin                                                 | 1    | -    | 1    | -    | -    | -    | 1    | 3    | -    |
| Nitrofurantoin                                            | 2    | 3    | 1    | -    | -    | -    | -    | -    | -    |
| Trimethoprim/sulfamethoxazole                            | 21   | 18   | 10   | -    | 2    | -    | 1    | 7    | 1    |
| Ciprofloxacin                                             | -    | 10   | 10   | 3    | 2    | 1    | 3    | 14   | 1    |
| Oxacillin                                                 | -    | 4    | 5    | 1    | -    | 2    | -    | 20   | 17   |
| Cephalexin                                                | -    | 10   | 8    | 2    | 2    | 1    | -    | 11   | 1    |
| Ceftriaxone                                               | 1    | -    | 1    | -    | -    | -    | -    | 3    | -    |
| Cefotaxime                                                | -    | -    | 1    | -    | -    | -    | -    | 2    | 1    |
| Cefoxazine                                                | 2    | -    | -    | -    | -    | -    | -    | -    | -    |
| Erythromycin                                              | -    | 10   | 7    | -    | -    | -    | -    | 11   | 3    |
| Chloramphenicol                                           | 34   | 26   | 10   | -    | -    | 1    | 2    | 3    | -    |
| Clindamycin                                               | -    | 7    | 6    | -    | -    | -    | -    | 4    | 3    |
| Total                                                     | 79   | 128  | 81   | 9    | 8    | 5    | 41   | 88   | 15   |
| Percentage                                                | 61.24 | 57.14 | 80.19 | 6.98 | 3.57 | 4.95 | 31.78 | 39.29 | 14.85 |
| Coagulase negative staphylococci                         |      |      |      |      |      |      |      |      |      |
| Vancomycin                                                | 46   | 51   | 29   | -    | 1    | -    | 1    | -    | -    |
| Gentamicin                                                | 17   | 28   | 9    | -    | 2    | 3    | 20   | 20   | 16   |
| Amikacin                                                 | 7    | 10   | 2    | -    | 1    | 1    | 5    | 1    | 1    |
| Ciprofloxacin                                             | 10   | 21   | 11   | -    | 1    | -    | 3    | 26   | 18   |
| Ofloxacin                                                 | -    | -    | -    | -    | -    | -    | 1    | -    | -    |
| Oxacillin                                                 | 3    | 6    | 4    | -    | 2    | -    | 28   | -    | 17   |
| Ampicillin                                                | 1    | -    | -    | -    | -    | -    | -    | -    | -    |
| Cephalexin                                                | 33   | 18   | 4    | -    | 1    | -    | 16   | 10   | 10   |
| Ceftriaxone                                               | 4    | 6    | -    | -    | -    | 1    | 7    | 6    | 3    |
| Cefoxazime                                                | 4    | 3    | 2    | -    | -    | -    | 10   | 2    | 1    |
| Cefotaxime                                                | -    | 1    | -    | -    | -    | -    | 3    | -    | -    |
| Nitrofurantoin                                            | 13   | 11   | 2    | -    | 1    | 2    | -    | -    | -    |
| Trimethoprim/sulfamethoxazole                            | 2    | 20   | 10   | -    | 1    | -    | 1    | 26   | 19   |
| Chloramphenicol                                           | 2    | 37   | 20   | 2    | -    | -    | 10   | 6    | 5    |
| Clindamycin                                               | -    | 14   | 5    | -    | 1    | -    | 9    | 17   |      |

Contd...
sulfamethoxazole and clindamycin can be considered as potentially favorable options for the treatment of *S. aureus* or even community acquired MRSA infections.

Two out of 11 (6.67%) *S. aureus* isolates were resistant to vancomycin during the study period. The first clinical vancomycin-resistant *S. aureus* (VRSA) in the world was isolated from a diabetic foot ulcer at the Michigan, US in 2002.[22] After that, several VRSA isolates confirmed by genetic analysis have been reported from different countries such as US, India, Pakistan, and Iran.[23] In Imam Khomeini Hospital in Tehran, Aligholi et al. identified 2 (0.56%) strains of VRSA confirmed by minimum inhibitory concentration of 64 and 512 mcg/ml for vancomycin as well as detection of vanA gene in 1 of the isolates through polymerase chain reaction (PCR).[24] At the same hospital in infectious diseases ward, Khalili et al. reported that 1.82% and 3.33% of detected *S. aureus* in 2009 and 2010 were resistant to vancomycin determined by the disc diffusion method.[15] A cross-sectional, observational study during 2 years at the nephrology and kidney transplant wards of Imam Khomeini Hospital demonstrated that all (100%) *S. aureus* isolates were sensitive to vancomycin.[17] Agar screening and PCR tests on 220 staphylococcal samples from three laboratories of Shiraz hospitals (Shahid-Faghihi, Namazi, and MRI) between March and December 2012 demonstrated that vanA and vanB resistant genes were positive in 34% and 37% of clinical isolates, respectively.[21] The development of VRSA could be attributed to overuse and selective pressure of vancomycin. In this regards, results of a cross-sectional study in a referral university-affiliated hospital in Shiraz at 2003 revealed that the prescription of vancomycin was only appropriate in 12 out of 200 (6%) patients according to the Hospital Infection Control Practice Advisory Committee guideline.[23] Although not studied yet, overuse of vancomycin for the empirical treatment of catheter-associated infections, as a common admission diagnosis in nephrology settings, can partially justify the current frequency of VRSA in our ward.

The sensitivity rate of CONS to vancomycin in our survey was high and did not change considerably during the 3 years period. This is in accordance with most of the other reports from Iran. Khoshbakht et al. reported that more than four-fifth (92.3%) of *Staphylococcus saprophyticus* isolates from urine of patients with urinary tract infection in Karaj was susceptible to vancomycin.[28] In addition, two investigations in Tehran hospitals demonstrated that all (100%) CONS from different biological samples were sensitive to vancomycin.[16,27] In contrast to vancomycin, most of CONS isolates (73.91–90.32%) in the present study were resistant to beta lactams such as oxacillin. Similarly, at three Makkah Hospitals in Saudi Arabia, Asghar reported that 82.4% of CONS were resistant to oxacillin.[19] Isolated CONS from

### Table 3: Contd...

| Antimicrobial agent/microorganism | Susceptibility |  |
|----------------------------------|---------------|--|
|                                  | Sensitive (n) | Intermediate (n) | Resistant (n) |
|                                  | 2013 | 2014 | 2015 | 2013 | 2014 | 2015 | 2013 | 2014 | 2015 |
| Erythromycin                     | 1    | 12   | 3    | -    | -    | -    | -    | 23   | 19  |
| Total                            | 110  | 253  | 115  | 6    | 7    | 11   | 86   | 138  | 126 |
| Percentage                       | 54.46 | 63.57 | 45.63 | 2.97  | 1.76  | 4.37 | 42.57 | 34.67 | 50  |
| Enterococcus spp.                |      |      |      |      |      |      |      |      |      |
| Vancomycin                       | 11   | 13   | 3    | 8    | 7    | 3    | 13   | 12   | 16  |
| Gentamicin                       | 2    | 1    | 1    | -    | 4    | 1    | 18   | 24   | 12  |
| Amikacin                         | 1    | 1    | -    | -    | -    | -    | 21   | 20   | 9   |
| Ciprofloxacin                    | 1    | -    | 1    | 2    | -    | 1    | 17   | 30   | 18  |
| Ofloxacin                        | 1    | -    | -    | -    | 1    | -    | 5    | 5    | -   |
| Nitrofurantoin                   | -    | 20   | 8    | 2    | 5    | 4    | 1    | -    | 2   |
| Chloramphenicol                  | 1    | 6    | 5    | -    | -    | -    | 2    | 3    | 3   |
| Erythromycin                     | -    | -    | 1    | -    | -    | -    | -    | 9    | 8   |
| Ampicillin                       | -    | 9    | 7    | -    | 6    | -    | 16   | 13   | 14  |
| Oxacillin                        | -    | -    | -    | -    | -    | -    | -    | 9    | 5   |
| Cephalexin                       | 1    | 4    | 1    | -    | 1    | 2    | 5    | 26   | 18  |
| Trimethoprim/sulfamethoxazole    | -    | 4    | 3    | -    | -    | 3    | 9    | 23   | 6   |
| Clindamycin                      | -    | -    | 1    | -    | -    | -    | -    | 3    | 5   |
| Total                            | 18   | 57   | 31   | 12   | 24   | 14   | 107  | 177  | 116 |
| Percentage                       | 13.14 | 22.1 | 19.25 | 8.76  | 9.3   | 8.69 | 78.1 | 68.6 | 72.05 |

*S. aureus=Staphylococcus aureus*
Northern population of Jordan revealed the resistance rate of 98.2% and 97.3% to ampicillin and penicillin, respectively. The resistance rate of Staphylococcus epidermidis to oxacillin at Imam Khomeini hospital in Tehran and Namazi Hospital in Shiraz was 57.1% and 100%, respectively. This disparity in the rate of S. epidermidis resistant to oxacillin in these two investigations can partially due to different study settings (all clinical wards vs. only ICUs, respectively), and the method of determining antibacterial resistance (disk diffusion vs. E-test, respectively).

Beside beta lactams, CONS exhibited high resistance to aminoglycosides including gentamicin (40–57.14%) in our study. This is relatively within the range (60–70%) in the US. Al Tayyar et al. reported that 49.3% of isolated CONS in different local hospitals of Jordan were resistant to gentamicin. The resistant rate of this pathogen to gentamicin in two hospitals in Tehran and one hospital in Shiraz was 42.9%, 87.5%, and 50%, respectively. Altogether, vancomycin appears to be remaining as the mainstay empirical and definite therapies of CONS infections in our center.

In our study, Enterococcus spp. exhibited high resistance rate to various antibacterials such as ampicillin, gentamicin, and especially, vancomycin. The frequency of VRE in developed countries such as US, most European countries (other than the UK and Ireland), UK, and Ireland is reported to be 30%, <10%, and up to 32%, respectively. The rate of VRE from different clinical settings in Iran varies considerably. For example, in an infectious diseases ward of Imam Khomeini Hospital in Tehran, between 6.7% and 18.75% of Enterococcus spp. isolates were resistant to vancomycin from 2007 to 2010. A cross-sectional study at different wards of the same hospital over 1 year period reported the VRE rate of 54.5%, Two studies from ICUs of two teaching hospitals demonstrated that all of Enterococcus spp. isolates were sensitive to vancomycin. In contrast, Askarian et al., at the same hospital, reported that 99 out of 700 patients (14%) were rectally colonized with VRE. Apart from type of study and method of detecting the pathogen, variation in possible risk factors of VRE colonization and infection can justify these different findings. In addition to vancomycin selection pressure and duration of treatment (>7 days), underlying disease, hemodialysis, and history of using a third generation cephalosporin have been also identified as associated factors of VRE in Namazi Hospital. Although not studied in our population, linezolid can be considered as an effective treatment option of VRE because at least two studies in Tehran and Shiraz teaching hospitals demonstrated that all Enterococcus spp. isolates were sensitive to this agent. In addition to linezolid, according to the present as well as Soltani et al. results, another potentially available, relatively low-cost antibiotic agent for the treatment of VRE in the studied centers is chloramphenicol.

The resistance rate of Enterococcus spp. to aminoglycosides (including gentamicin and amikacin) during our study period was high and ranged from 88% to 92.86%. Three studies on hospital-acquired urinary tract infections from Tehran and Karaj hospitals reported that between 40% and 100% of Enterococcus spp. isolates were resistant to either amikacin or gentamicin. Samanipour et al. reported that Enterococcus spp. isolates from a nephrology ward at Tehran were resistant to gentamicin in 75% of cases. It has been showed that 66.7% of isolated Enterococcus spp. from two ICUs in Shiraz (including Namazi Hospital) was resistant to gentamicin. Widespread use of aminoglycosides for both outpatients and inpatients seems to be the major cause of aminoglycoside resistance. In this regards, Vessal et al. reported that cefazolin plus gentamicin was the most commonly used preoperative antibiotic prophylaxis regimen at the surgical ward of Namazi Hospital in March 2010. Apart from this, overuse of these medications in the agriculture as well as animal husbandry can also account for high resistance to aminoglycosides. High levels of gentamicin-resistant Enterococcus faecalis and Enterococcus faecium have been detected in the human food supply. High resistance to aminoglycosides can challenge the combination treatment of Enterococcus spp. infections such as infective endocarditis because these agents are usually administered with beta lactams or glycopeptides as synergistic therapy.

The present survey had 5 major limitations. First, the retrospective pattern of the study precluded comparing the results of patients’ antibiotic gram with their clinical condition and response to antimicrobial treatment. Second, determination of antimicrobial susceptibility was performed by the classic disc diffusion method. Currently, more reliable and accurate methods such as microbroth dilution or E-test are recommended. Third, vanA and vanB genes were not determined by PCR to confirm isolates suspected to VRSA and VRE. Fourth, our hospital laboratory was not capable of distinguishing Enterococcus faecalis from Enterococcus faecium or Streptococcus viridans from Streptococcus pneumoniae isolates during the study period. Finally, some necessary antibiotic discs such as linezolid, teicoplanin, and rifampin were not routinely considered by the hospital laboratory for assessing antimicrobial susceptibility of isolated S. aureus and Enterococcus spp.
S. aureus was the most frequent Gram-positive pathogen isolated from all samples. The rate of ORSA in our clinical setting was considerably high. In addition, 6.67% of S. aureus isolates were resistant to vancomycin. The sensitivity rate of CONS to vancomycin was high and did not change considerably during the 3 years period. Vancomycin can be remained as the first line empirical and definite treatment of CONS. The rate of VRE increased considerably (from 40.63% to 72.73%) during the study period. The resistance rate of CONS as well as Enterococcus spp. to aminoglycosides was also high. Lack of appropriate infection control activities and antimicrobial selection pressure due to antibiotic overuse may be the main reasons for our concerning findings about high rates of ORSA and VRE.

Antimicrobial stewardship programs including education and guideline implementation (e.g., active participation of clinical pharmacists and microbiologists in antibacterial therapy), preventive strategies (e.g., antimicrobial lock solution for prevention of catheter-associated infection), formulary and restriction strategies (dispensing linezolid or teicoplanin only after the verification of infectious disease service), review and feedback strategies (e.g., reviewing antimicrobial orders for catheter-associated infections), computer-assisted strategies (e.g., computerized physician order-entry and automatic stop orders), and antibiotic cycling strategies (e.g., using chloramphenicol instead of aminoglycosides for treatment of CONS or VRE) seems to be the last ditch to encounter and manage the antibacterial resistance dilemma in our center.

AUTHORS’ CONTRIBUTION

Iman Karimzadeh contributed in study design, data analysis, and manuscript review. Mona Mirzae contributed in data collection and manuscript drafting. Niloofar Sadeghimanesh contributed in data collection and manuscript drafting. Mohammad Mahdi Sagheb contributed in data interpretation and manuscript review.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. World Health Organization (WHO). The Top 10 Causes of Death. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/. [Last accessed on 2016 Mar 13].
2. Rossolini GM, Thaller MC. Coping with antibiotic resistance: Contributions from genomes. Genome Med 2010;2:15.
3. Fish DN, Ohlinger MJ. Antimicrobial resistance: Factors and outcomes. Crit Care Clin 2006;22:291-311, vii.
4. The State of the World’s Antibiotic; 2015. Available from: https://www.cdc.gov/antibiotic-use/clinicians/pdf/2015_report.pdf. [Last accessed on 2016 Mar 13].
5. Gendel I, Azzam ZS, Braun E, Levy Y, Krivoy N. Antibiotic utilization prevalence: Prospective comparison between two medical departments in a tertiary care university hospital. Pharmacoeconomics Drug Saf 2004;13:735-9.
6. Hatam N, Askarian M, Moravveji AR, Assadian O. Economic burden of inappropriate antibiotic use for prophylactic purpose in Shiraz, Iran. Iran Red Crescent Med J 2011;13:234-8.
7. Rossolini GM, Mantengoli E, Montagnani F, Pollini S. Epidemiology and clinical relevance of microbial resistance determinants versus anti-gram-positive agents. Curr Opin Microbiol 2010;13:582-8.
8. Menichetti F. Current and emerging serious gram-positive infections. Clin Microbiol Infect 2005;11 Suppl 3:22-8.
9. Nordmann P, Naas T, Fortineau N, Poirel L. Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010. Curr Opin Microbiol 2007;10:436-40.
10. Couto I, Pereira S, Miragaia M, Sanches IS, de Lencaestre H. Identification of clinical staphylococcal isolates from humans by internal transcribed spacer PCR. J Clin Microbiol 2001;39:3099-103.
11. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. Available from: http://www.micróbio.com.br/images/NCIPD_docs/CLSI_M100-S24.pdf. [Last accessed on 2016 Jan 10].
12. Japoni A, Farshad S, Alborzi A, Kalani M, Rafaatpour N, Oboudi B, et al. Epidemiology and antibacterial susceptibility patterns of bloodstream infections, 2001-2004: An experience with BACTEC 9240 in Southern Iran, Pak J Biol Sci 2008;11:422-7.
13. Japoni A, Vazin A, Davarpanah MA, Afkhami Ardakani M, Alborzi A, Japoni S, et al. Ventilator-associated pneumonia in Iranian intensive care units. J Infect Dev Ctries 2011;5:286-93.
14. Hassanzadeh P, Motamedifar M, Hadi N. Prevalent bacterial infections in intensive care units of Shiraz University of Medical Sciences Teaching Hospitals, Shiraz, Iran. Jpn J Infect Dis 2009;62:249-53.
15. Khalili H, Dashti-Khavidaki S, Karimzadeh I, Jafari S, Abdollahi A, Shahidi MR et al. Changes in 4-year antimicrobial resistance pattern of gram-positive bacteria at the main referral teaching hospital, Tehran, Iran. Acta Med Iran 2012;50:493-504.
16. Soltani R, Khalili H, Abdollahi A, Rossoleimad J, Dasthi-Khavidaki S. Nosocomial gram-positive antimicrobial susceptibility pattern at a referral teaching hospital in Tehran, Iran. Future Microbiol 2012;7:903-10.
17. Samanipour A, Dashti-Khavidaki S, Abbasi MR, Abdollahi A. Antibiotic resistance patterns of microorganisms isolated from nephrology and kidney transplant wards of a referral academic hospital. J Res Pharm Pract 2016;5:43-51.
18. Mozaffari K, Bakshshandeh H, Khalaj H, Soudi H. Incidence of catheter-related infections in hospitalized cardiovascular patients. Res Cardiovasc Med 2013;2:99-103.
19. Asghar AH. Frequency and antibiotic susceptibility of gram-positive bacteria in Makkah hospitals. Ann Saudi Med 2011;31:462-8.
20. Woodford N, Livermore DM. Infections caused by gram-positive bacteria: A review of the global challenge. J Infect 2009;59 Suppl 1:S4-16.

21. National Center of Rational Use Drug. Available from: http://www.fdo.behdasht.gov.ir/uploads/114_1363_8_iran90.pdf. [Last accessed on 2016 Mar 14].

22. Centers for Disease Control and Prevention (CDC). Staphylococcus aureus resistant to vancomycin – United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-7.

23. Saadat S, Solhjoo K, Norooz-Nejad MJ, Kazemi A. VanA and VanB positive vancomycin-resistant Staphylococcus aureus among clinical isolates in Shiraz, South of Iran. Oman Med J 2014;29:335-9.

24. Aligholi M, Emaneini M, Jabalameli F, Shahsavan S, Dabiri H, Sedaght H. Emergence of high-level vancomycin-resistant Staphylococcus aureus in the Imam Khomeini Hospital in Tehran. Med Princ Pract 2008;17:432-4.

25. Askarian M, Assadian O, Safaei G, Golkar A, Namazi S, Movahed MR. Vancomycin use in a large teaching hospital in Shiraz, Islamic Republic of Iran, 2003. East Mediterr Health J 2007;13:1195-201.

26. Khoshbakht R, Salimi A, Shirzad Aski H, Keshavarzi H. Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Karaj, Iran. Jundishapur J Microbiol 2013;6:86-90.

27. Tayebi Z, Seyediavadi SS, Goudarzi M, Rahimi MK, Boromandi S, Bostanabad SZ, et al. Frequency and antibiotic resistance pattern in gram positive uropathogenes isolated from hospitalized patients with urinary tract infection in Tehran, Iran. J Genes Microbes Immun 2014;2014:1-9.

28. Al Tayyar IA, Al-Zoubi MS, Hussein E, Khudairat S, Sarosiekf K. Prevalence and antimicrobial susceptibility pattern of coagulase-negative staphylococci (CoNS) isolated from clinical specimens in Northern of Jordan. Iran J Microbiol 2015;7:294-301.

29. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85.

30. Jones RN, Ross JE, Castanheira M, Mendes RE. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn Microbiol Infect Dis 2008;62:416-26.

31. Askarian M, Afkhamzadeh R, Monabbati A, Daxboeck F, Assadian O. Risk factors for rectal colonization with vancomycin-resistant enterococci in Shiraz, Iran. Int J Infect Dis 2008;12:171-5.

32. Ghadiri H, Vaez H, Khoosravi S, Soleymani E. The antibiotic resistance profiles of bacterial strains isolated from patients with hospital-acquired bloodstream and urinary tract infections. Crit Care Res Pract 2012;2012:890797.

33. Vessal G, Namazi S, Davarpanah MA, Foroughinia F. Evaluation of prophylactic antibiotic administration at the surgical ward of a major referral hospital, Islamic Republic of Iran. East Mediterr Health J 2011;17:663-8.

34. McDonald LC, Lauderdale TL, Shiau YR, Chen PC, Lai JF, Wang HY, et al. The status of antimicrobial resistance in Taiwan among gram-positive pathogens: The Taiwan surveillance of antimicrobial resistance (TSAR) programme, 2000. Int J Antimicrob Agents 2004;23:362-70.